▲ Peaking
Business
Amgen drops ph. 1 obesity drug, upping pressure on MariTide
Amgen pivots its obesity strategy by terminating an early-stage drug candidate while simultaneously raising its overall sales outlook.
1 trends tracked about this subject — the full history, oldest to newest below.
Amgen pivots its obesity strategy by terminating an early-stage drug candidate while simultaneously raising its overall sales outlook.